<SEC-DOCUMENT>0001193125-25-239836.txt : 20251015
<SEC-HEADER>0001193125-25-239836.hdr.sgml : 20251015
<ACCEPTANCE-DATETIME>20251015120729
ACCESSION NUMBER:		0001193125-25-239836
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251015
FILED AS OF DATE:		20251015
DATE AS OF CHANGE:		20251015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		251394068

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d10882d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:15pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:15pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of October 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#8217;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &#9746;&#8195;&#8195;Form <FONT STYLE="white-space:nowrap">40-F</FONT> &#9744; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In October 2025, Sanofi published the press release attached hereto as Exhibit 99.1 which is incorporated
herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><U>Exhibit No.</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>Description</U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="21"></TD>
<TD HEIGHT="21" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d10882dex991.htm">Press Release dated October&nbsp;8, 2025: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase&nbsp;
2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors</A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: October&nbsp;15, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5" ALIGN="center">SANOFI</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="27"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">/s/&nbsp;Alexandra Roger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:9pt">Name: Alexandra Roger</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:9pt">Title: Head of Legal Corporate&nbsp;&amp; Finance</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d10882dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-family:Verdana; font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g10882img1.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g10882img2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (<SUP
STYLE="font-size:75%; vertical-align:top">212</SUP><FONT STYLE="white-space:nowrap">Pb-DOTAMTATE)</FONT> achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic
neuroendocrine tumors </I></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt">AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> showed prolonged and clinically meaningful benefits
across <FONT STYLE="white-space:nowrap">PRRT-na&iuml;ve</FONT> and PRRT-exposed patients with unresectable or metastatic <FONT STYLE="white-space:nowrap">GEP-NETs,</FONT> highlighting the potential of Targeted Alpha Therapy with <FONT
STYLE="white-space:nowrap">lead-212</FONT> as a new treatment option </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:10pt">Results will form the basis of future discussions with health authorities </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><B>Paris, October</B><B></B><B>&nbsp;8, 2025.</B>&nbsp;Positive results from the <FONT STYLE="white-space:nowrap">ALPHAMEDIX-02</FONT> phase 2 study
(clinical study identifier:&nbsp;<FONT STYLE="font-family:Verdana; font-size:10pt" COLOR="#7a00e6"><U>NCT05153772</U></FONT><FONT STYLE="font-family:Verdana">) showed AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (<SUP
STYLE="font-size:75%; vertical-align:top">212</SUP><FONT STYLE="white-space:nowrap">Pb-DOTAMTATE),</FONT> an investigational somatostatin receptor (SSTR)-Targeted Alpha Therapy using the <FONT STYLE="white-space:nowrap">lead-212</FONT> isotope, met
all primary efficacy endpoints and showed clinically meaningful overall response rates (ORR) and prolonged clinical benefits in both peptide receptor radionuclide therapy <FONT STYLE="white-space:nowrap">(PRRT)-na&iuml;ve</FONT> and PRRT-exposed
patients with unresectable or metastatic SSTR positive gastroenteropancreatic neuroendocrine tumors <FONT STYLE="white-space:nowrap">(GEP-NETs).</FONT> Benefits in key secondary endpoints, including progression-free survival (PFS) and overall
survival (OS), were also observed across both cohorts. AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> had a manageable safety profile that was similar across both cohorts. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Verdana" ALIGN="justify"><I>&#8220;The positive results from the <FONT STYLE="white-space:nowrap">ALPHAMEDIX-02</FONT> study represent a pivotal movement for
the Orano Med <SUP STYLE="font-size:75%; vertical-align:top">212</SUP><FONT STYLE="white-space:nowrap">Pb-based</FONT> platform and underscore the profound potential of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">lead-212-based</FONT></FONT> radiopharmaceuticals in addressing critical unmet needs for patients with <FONT STYLE="white-space:nowrap">GEP-NETs.</FONT> We are very encouraged by
AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&#8217;s consistent and clinically meaningful activity across both peptide receptor radionuclide therapy <FONT STYLE="white-space:nowrap">(PRRT)-na&iuml;ve</FONT> and PRRT-exposed
patients,&#8221; said </I><B>Volker Wagner</B><I>, MD, PhD, Chief Medical Officer at Orano Med. &#8220;These data reinforce our belief that delivering highly potent alpha-emitters directly to cancer cells could potentially offer a meaningful new
treatment option for people living with <FONT STYLE="white-space:nowrap">GEP-NETs.&#8221;</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Alpha-emitters are being studied to
determine their relative potency and targeted tumor activity compared to current approved therapies. It is believed they could potentially reduce exposure of surrounding healthy tissue due to the short range of alpha particles. In February 2024,
AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) for treatment of <FONT STYLE="white-space:nowrap">PRRT-na&iuml;ve</FONT> patients with
unresectable or metastatic, progressive SSTR-expressing <FONT STYLE="white-space:nowrap">GEP-NETs,</FONT> recognizing the potential clinical benefits and potential of this <FONT STYLE="white-space:nowrap">lead-212&#8211;based</FONT> therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Verdana" ALIGN="justify"><I>&#8220;The promising <FONT STYLE="white-space:nowrap">ALPHAMEDIX-02</FONT> results represent a significant step forward,
reinforcing the potential of targeted alpha therapy to deliver precise treatment for <FONT STYLE="white-space:nowrap">GEP-NETs,&#8221;</FONT> said </I><B>Christopher Corsico</B><I>, MD, Global Head of Development at Sanofi. &#8220;These data,
demonstrating clinically meaningful activity and a manageable safety profile, underscore our unrelenting commitment to developing innovative therapies for patients with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers. We look forward to advancing AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> and working with Orano Med and regulators
to bring this important treatment to the <FONT STYLE="white-space:nowrap">GEP-NET</FONT> community as soon as possible.&#8221; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">The study is
ongoing, and the full results will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress. The results will also form the basis of discussions with health authorities.
AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> has not been approved by any regulatory authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="right">1/3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>About the <FONT STYLE="white-space:nowrap">ALPHAMEDIX-02</FONT> study </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana"><FONT STYLE="white-space:nowrap">ALPHAMEDIX-02</FONT> is a phase 2, open-label, multicenter study evaluating the efficacy and safety of AlphaMedix<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (<SUP STYLE="font-size:75%; vertical-align:top">212</SUP><FONT STYLE="white-space:nowrap">Pb-DOTAMTATE)</FONT> in patients with histologically confirmed unresectable or metastatic <FONT
STYLE="white-space:nowrap">GEP-NETs,</FONT> positive somatostatin analogue imaging and at least one site of measurable disease. The study included two cohorts evaluating <FONT STYLE="white-space:nowrap">PRRT-na&iuml;ve</FONT> (n=35) and PRRT-exposed
(n=26) patients. PRRT-exposed patients had progressive disease after receiving up to four doses of <SUP STYLE="font-size:75%; vertical-align:top">177</SUP><FONT STYLE="white-space:nowrap">Lu-DOTATATE</FONT> and received their last dose at least six
months prior to Day 1. In both cohorts, AlphaMedix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> was administered at 67.6 &micro;Ci/kg every eight weeks for up to four cycles (6 mCi maximum per cycle). Primary endpoints included ORR per
RECIST1.1 and safety. Secondary endpoints included PFS and OS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>About NETs </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">NETs are a heterogeneous group of cancers that originate from neuroendocrine cells. These cancers occur mostly in the gastrointestinal tract and
pancreas but can also occur in other tissues including the thymus, lung, and other uncommon sites such as the ovaries, heart, and prostate. Most NETs strongly express somatostatin receptors. Despite the global prevalence of NETs increasing each
year, it is considered a rare cancer that is estimated to affect approximately 35/100,000 individuals worldwide. In the United States, around 12,000 patients annually are expected to be diagnosed with neuroendocrine tumors, with an average five-year
survival rate of 60% at a metastatic stage. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>About Orano Med </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Orano Med
is a subsidiary of the Orano Group. Orano Med is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer using the unique properties of <FONT STYLE="white-space:nowrap">lead-212</FONT> (<SUP
STYLE="font-size:75%; vertical-align:top">212</SUP>Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha Therapy (TAT). Leveraging its unique and secured access to <SUP
STYLE="font-size:75%; vertical-align:top">212</SUP>Pb, the company is developing several treatments using<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;212</SUP>Pb combined with various targeting agents. Orano Med has<SUP
STYLE="font-size:75%; vertical-align:top">&nbsp;212</SUP>Pb manufacturing facilities, laboratories, and R&amp;D centers in France and in the US and is currently expanding its <FONT STYLE="white-space:nowrap">GMP-manufacturing</FONT> capacities for<SUP
STYLE="font-size:75%; vertical-align:top">&nbsp;212</SUP>Pb radiolabeled pharmaceuticals in North America and Europe. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>About Sanofi
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Sanofi is an R&amp;D driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#8217;s
lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions
more.&nbsp;Our team is guided by one purpose: we chase the miracles of science to improve people&#8217;s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent
healthcare, environmental, and societal challenges of our time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Sandrine Guendoul</B> |
+33 6 25 09 14 25 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Evan Berland</B> | +1 215 432 0234 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>L&eacute;o Le Bourhis</B> | +33 6 75 06 43 81 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Victor
Rouault</B> | +33 6 70 93 71 40 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Timothy Gilbert</B> | +1 516 521 2929 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>L&eacute;a Ubaldi</B><B></B>&nbsp;| +33 6 30 19 66 46 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>lea.ubaldi@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT
 COLOR="#7a00e6"><I>Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Thomas Kudsk Larsen</B> | +44 7545 513 693 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Aliz&eacute;
Kaisserian</B> | +33 6 47 04 12 11 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Felix Lauscher</B> | +1 908 612 7239 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Keita Browne</B> | +1 781 249 1766 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Nathalie
Pham</B> | +33 7 85 93 30 17 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Tarik Elgoutni</B> | +1 617 710 3587 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Thibaud Ch&acirc;telet</B> | +33 6 80 80 89 90 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Yun
Li</B>&nbsp;| +33 6 84 00 90 72 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="right">2/3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I><U>Orano Med</U> </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Sophie Letournel</B><B><U></U></B>&nbsp;|&nbsp;+33 6 38 44 34 11|
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>sophie.letournel@orano.group</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Orano Press
Office</B><B></B>&nbsp;|&nbsp;+33 (0)1 34 96 12 15| <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>press@orano.group</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana"><B>Sanofi forward-looking statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><I>This press release
contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221; and similar expressions. Although
Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of
which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of
such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities,
to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,&nbsp;trends in exchange rates and prevailing
interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi,
including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in Sanofi&#8217;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended
December&nbsp;31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><I>All trademarks mentioned in this press release are the property of the Sanofi group except for Orano Med and AlphaMedix<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="right">3/3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g10882img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10882img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  O *@# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#XS_ ."B7[=S?LI>'[#PYX7A@O?B
M#K<#30&X&Z+3K?)7[0Z_Q,6#!%/&58G@88 _(?5?VDOCO\4=6FNI/'_C35[L
M9D>/3[^X5$'J(X2%4?0 4 ?I[_P3I^('Q.;]C#XF>+O$>JZUXBUG3[J_.BIK
MDDEQ*!!9QL IDRQ7S"1C/52!WKU,JP]+%8^AAZ[M"<XI^C:3.G#0C5KPA/9M
M)_>?/_P1_:-^)\/QM\-W2^*M8UB;4]5@@NK"ZNGEAN5DD563RR=HX8XP!MXQ
MC%?U9G?#N42RJM!T(P4(-II)--*Z=]_6^_4_3,9E^$>%FN1*R=G;:R[GZF?&
M+XY>!_@'X5?Q#XZ\06N@Z<"5C$I+2W#_ -R*-<M(WLH..^!7\?GY4?'&M?\
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M1KV$DL<RN?Q$$?Y"@#XF_P""D7_)[?Q2_P"ORW_])(* /V"_X)R_\F4?"O\
MZ\)O_2F:@#TC]I?_ )-Q^*O_ &*FJ_\ I'+0!_/+^S=_R<3\+?\ L:M*_P#2
MN*@#]QOBY\2_V;OCUK#?##QS=:9X@NC<FTB\^WD @N"=N(KH >6V>,JP!/&:
M^P_U1SI8/Z][!\EN;=7MO>U[[:[7/5_LO&>R]MR>[:_G;TW/F;XQ_P#!%/P]
MJ,<]W\,O&EWH]SRR:;X@07$!]%$R .H]RKU\>>4?F9\;O@?XP_9V^(5UX/\
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M5_\ 7A-_Z4S4 >D?M+_\FX_%7_L5-5_](Y: /YY?V;O^3B?A;_V-6E?^E<5
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M(S\K@$CH01C !^0WQ5_8X^*_P9U=M/\ $WAV&!^=DMOJ-O*D@]1A\@?4 ^U
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MGW5+')*/@9)(8#@ 'YL:Y^SE\1/#FO'1M1\/?9]2#^7Y/VVW;YLXQN60C]:
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=3M/\06%Y=7#:O9.(XHKA'=MJS%CA5/ !)H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g10882img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10882img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  _ 1,# 1$  A$! Q$!_\0
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M=#%KD:M)'KJUQW;W/:\AU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MOMD!CE21<'ZH* .:_9K_ &7?"O[+NAZSI?A6>]GM]4N$N9C>R;R&5=HQ[8H
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( * "@ H _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
